Latest news with #Marea
Forbes
29-05-2025
- Lifestyle
- Forbes
New York Restaurants June 2025: Where To Go
Locanda Verde Edible enlightenment from our eatery experts and colleagues Monie Begley, Richard Nalley and Randall Lane, as well as brothers Bob, Kip and Tim. Santi; Photo by evan sung Chef Michael White, creator of Marea and Ai Fiori, has a new Midtown restaurant that's already a hit. The setting is multilevel and luxurious, but the pan-Italian fare is the draw. To start, try the delicious risotto—a creamy portion of acquarella rice and veal sausage mixed with chestnut and fontina; or the garganelli, tossed with parma prosciutto, English peas and truffle butter. Main courses are on par: The spigola—a delicately cooked black bass—is accompanied by squash blossom; the astice is a juicy Maine lobster served on a mound of white asparagus and morels; the vitello is a perfectly pink chop served with asparagus in a pancetta sauce. End your meal with the delizie al limone, a white chocolate ball filled with an airy sponge cake with limoncello. Locanda Verde It's a happy surprise to walk into a steel-and-glass skyscraper and find oneself in a richly paneled room with a gas fireplace. Steak tartare and lamb meatball sliders are a great opening act for a simply grilled Ligurian tuna antipasto salad or the tortelli di zucca, a squash-filled, slightly sweet ravioli. Three delectable desserts: the alpine honey cake, the olive oil panna cotta with wedges of grapefruit and kumquats and the grapefruit and Campari ice with shavings. BEA A good bet for a casual place for dinner before hitting a Broadway show. Highlights: manicotti stuffed with ground chicken, ricotta and mozzarella; miso salmon; and herb roasted chicken with toasted farro and mushroom crème sauce. As a vegetarian option, the eggplant and tofu is a great success. Skip the banana sundae and go for either the chocolate chip brownie à la mode or the panna cotta—both scrumptious. (Make a point of noting the start time of your show, as there can be long pauses between courses.) César Forgive the less than gracious welcome behind a locked entrance as well as the insistent waiter trying to upsell you on the already pricey prix fixe tasting menu, and a heavenly dinner will be your reward. Opt for the eight-course fish menu, as the succession of creatively conceived and exquisitely prepared dishes without a miss is astonishing. The bluefin tuna parfait and the foie gras flan with crab and wood ear mushroom are especially memorable. The fine Italian dining here is as expensive as you'd expect on the Upper East Side. The melon that accompanies the perfect prosciutto isn't quite ripe enough, but the Caesar salad is better than Grandma used to make. The Dover sole with lemon sauce and the duck à l'orange are first rate. The ricotta cheesecake and the tiramisu are excellent. Cozy atmosphere, with friendly and professional service. BG This quiet oasis on the seventh floor at Bergdorf 's is a civilized place for a Midtown lunch, with a classically decorated setting with views over Central Park. The mushroom tart is just the right size to leave room for the perfectly seared sea scallops. The clam chowder is tasty but has more corn than clams. Save room for a delightful strawberry shortcake or, if it's on the menu, key lime pie. METROPOLIS BY MARCUS SAMUELSSON; photo byLocated on the second floor inside the Perelman Performing Arts Center (a no-car zone), this is a sleek, modern place to have lunch or dinner if you're visiting the World Trade Center and environs. The limited menu is excellent: The salad with branzino is a particular success, and the French omelette is incomparable. The banana pudding is worth a visit all by itself. ly ly vietnamese cook house A joyful, jam-packed place serving authentic Vietnamese specialties. It employs a combination of fine Asian spices with an overlay of French finesse gained through nearly five decades of French rule. Visit with a group, as tasting all the colorful and delicious offerings is great fun. Begin with a round of salt-and-pepper squid, lightly fried with jalapeño, cherry tomatoes and crispy garlic. The bánh xèo is a crèpe with pork belly, shrimp, bean sprout, scallion and nuoc mam (traditional fish sauce and lime). The papaya salad is a must. The pho is a rich noodle soup of rice vermicelli cooked for 20 hours with cilantro, onions and scallions. It can be served with slow-cooked short ribs. There are a variety of spring rolls from which to choose. Other delectable dishes are the Saigon shaking beef, the lump crab noodles and the Saigon hawker rice—lemongrass pork chop, with a bit of steamed Vietnamese meatloaf and a fried egg.
The Star
26-05-2025
- Business
- The Star
Pantai Hillpark residents bag nearly 2,900kg of recyclables in three months to win competition
Devakumaran (second from right) receiving the award from Benetello (right). With them are Chew (left) and Rosli. — AZHAR MAHFOF/The Star COMMUNITY spirit and a commitment to the environment have helped residents of a Kuala Lumpur strata property emerge as champions in a recycling competition. Pantai Hillpark Phase 5 residents collected 2,894.6kg of recyclables over three months, earning them the top spot in the Strata Recycling Competition (KL Edition) under the #MyHomeRecycling campaign. Management corporation (MC) chairman P. Devakumaran credited the residents for their consistent efforts and teamwork. 'We decided to participate in the programme as we noticed that we had a lot of recyclables that were being discarded. 'We joined the programme around September last year and the response has been very good. 'There were some teething issues but we managed to sort these out,' he said during a prize presentation event. Devakumaran added that the competition was a good way to promote recycling within the community while generating a small income. He said proceeds from the sale of recyclables were shared between the MC and cleaners. The competition was organised by Riiicycle Tech Sdn Bhd in collaboration with the non-governmental organisa- tions (NGOs) Malaysian Recycling Alliance (Marea) and GreenWeive. Supported by SWCorp Wilayah Persekutuan, the contest aims to promote recycling among residents of high-rise and strata properties. These residents are encouraged to trade in their recyclable items for redeemable vouchers using the Riiicycle app. Riiicycle founder Chew Chin Huat explained that the competition was designed to encourage awareness by offering incentives to participants. 'We want to turn recycling awareness into action through an infrastructure-knowledge sharing approach. 'In our first phase, we approached strata properties in Kuala Lumpur to participate, and now, we have about 15 properties on board. 'Entering phase two, Riiicycle aims to scale the initiative further by inviting more strata communities and high-rise residential areas to take part in this collective environmental effort.' He added that top recyclers would be awarded every three months. Between January and April, a total of 25,838.66kg of recyclables were collected from the city's high-rise residents. Marea chief executive officer Roberto Benetello emphasised the NGO's role in driving the transition toward a recycling ecosystem by promoting circular economy practices and supporting the adoption of Extended Producer Responsibility (EPR). 'With EPR, the responsibility for managing packaging waste falls on the companies. 'This approach not only helps protect the environment but also supports the development of a circular economy. 'Recycled packaging is transformed into secondary products, which helps reduce the need for raw materials,' he said. Benetello added the goal was to keep raw materials in circulation for as long as possible as a way of minimising waste and promoting more sustainable consumption patterns. A prize presentation ceremony was held to award participants as well as recipients of a lucky draw. Cash prizes totalling RM3,500 were awarded during the ceremony. Also present were Lembah Pantai Federal Territories Residents Representative Council (MPPWP) sub-zone 3 chairman Rosli Ishak and representatives from SWCorp.
Yahoo
16-05-2025
- Business
- Yahoo
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Publication follows late-breaking oral presentation of Phase 2a results at the 93rd EAS Congress; MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks Second publication of MAR001 preclinical results in eBioMedicine that demonstrate improved plasma lipid profiles SOUTH SAN FRANCISCO, Calif., May 16, 2025--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that positive results from a Phase 2a clinical trial of MAR001 were published in The Lancet entitled "Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies." The publication follows a recent late-breaking oral presentation of the Phase 2a results at the 93rd EAS Congress and can be accessed here. In addition, Marea announced a publication of MAR001 preclinical results in the peer-reviewed journal eBioMedicine entitled "A Novel ANGPTL4 Inhibitory Antibody Safely Improves Lipid Profiles in Non-Human Primates." The publication can be accessed here. MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. Results from Marea's Phase 2a clinical trial of MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks with a favorable safety profile. "We are excited to have our MAR001 Phase 2a clinical results and preclinical data recognized within the broader scientific community through these publications in The Lancet and eBioMedicine," said Ethan Weiss, M.D., chief scientific officer of Marea. "These findings validate ANGPTL4 inhibition and the ability of MAR001 to safely and effectively reduce remnant cholesterol and triglycerides, which align with genetic findings and support further development in addressing atherosclerotic cardiovascular disease risk. We look forward to initiating a Phase 2b trial of MAR001 in the second quarter of 2025." About Remnant Cholesterol Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes, or obesity. There are currently no available targeted therapies to lower remnant cholesterol and improve metabolic function. About MAR001 MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower remnant cholesterol and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower remnant cholesterol, improved adipose distribution, improved insulin sensitivity, lower triglyceride levels, and protection from cardiovascular disease and type 2 diabetes. MAR001 is being developed to reduce the risk of major adverse cardiovascular events (MACE) in adults with established atherosclerotic cardiovascular disease (ASCVD) plus elevated triglycerides and remnant cholesterol. Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. Results from a Phase 2a study of MAR001 demonstrated clinically meaningful reductions in remnant cholesterol and triglycerides. Marea plans to advance MAR001 into Phase 2b clinical development in the second quarter of 2025. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit and follow us on LinkedIn and X. View source version on Contacts Media Contact:Katie Engleman, 1ABkatie@
Business Wire
16-05-2025
- Business
- Business Wire
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that positive results from a Phase 2a clinical trial of MAR001 were published in The Lancet entitled 'Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.' The publication follows a recent late-breaking oral presentation of the Phase 2a results at the 93rd EAS Congress and can be accessed here. In addition, Marea announced a publication of MAR001 preclinical results in the peer-reviewed journal eBioMedicine entitled 'A Novel ANGPTL4 Inhibitory Antibody Safely Improves Lipid Profiles in Non-Human Primates.' The publication can be accessed here. MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. Results from Marea's Phase 2a clinical trial of MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks with a favorable safety profile. 'We are excited to have our MAR001 Phase 2a clinical results and preclinical data recognized within the broader scientific community through these publications in The Lancet and eBioMedicine,' said Ethan Weiss, M.D., chief scientific officer of Marea. 'These findings validate ANGPTL4 inhibition and the ability of MAR001 to safely and effectively reduce remnant cholesterol and triglycerides, which align with genetic findings and support further development in addressing atherosclerotic cardiovascular disease risk. We look forward to initiating a Phase 2b trial of MAR001 in the second quarter of 2025.' About Remnant Cholesterol Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes, or obesity. There are currently no available targeted therapies to lower remnant cholesterol and improve metabolic function. About MAR001 MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower remnant cholesterol and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower remnant cholesterol, improved adipose distribution, improved insulin sensitivity, lower triglyceride levels, and protection from cardiovascular disease and type 2 diabetes. MAR001 is being developed to reduce the risk of major adverse cardiovascular events (MACE) in adults with established atherosclerotic cardiovascular disease (ASCVD) plus elevated triglycerides and remnant cholesterol. Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. Results from a Phase 2a study of MAR001 demonstrated clinically meaningful reductions in remnant cholesterol and triglycerides. Marea plans to advance MAR001 into Phase 2b clinical development in the second quarter of 2025. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit and follow us on LinkedIn and X.
Yahoo
07-05-2025
- Health
- Yahoo
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
MAR001, a first-in-class monoclonal antibody targeting ANGPTL4, demonstrated approximately 53% placebo-adjusted mean reduction in remnant cholesterol and placebo-adjusted mean reduction in triglycerides at 12 weeks Approximately 65% placebo-adjusted mean reduction in remnant cholesterol and triglycerides in participants with greater triglyceride elevation at baseline (≥200 mg/dl) MAR001 was generally well tolerated; Phase 2b study expected to initiate in second quarter of 2025 Second oral presentation at EAS describes association of remnant cholesterol levels with major cardiovascular events in patients with atherosclerotic cardiovascular disease, underscoring potential of MAR001 to become an important new therapeutic option SOUTH SAN FRANCISCO, Calif., May 07, 2025--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today presented positive data from a Phase 2a clinical trial of MAR001 in a late-breaking oral session at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK. MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. "We are very excited by these data from our Phase 2a study, which demonstrate the strong potential of MAR001 to address the most important unaddressed lipid and metabolic drivers of atherosclerotic cardiovascular disease in high-risk patients," said Josh Lehrer, M.D., FACC, chief executive officer of Marea. "We look forward to advancing MAR001 into Phase 2b development for treating residual cardiovascular risk in patients who remain at highest risk despite aggressive standard of care therapies." "Atherosclerotic cardiovascular disease patients with elevated remnant cholesterol remain at an increased risk for major adverse cardiovascular events despite best available standard of care therapies," said Ethan Weiss, M.D., chief scientific officer of Marea. "These data clearly validate the ability of MAR001 to significantly lower remnant cholesterol and triglycerides by inhibiting ANGPTL4, supporting genetic findings and expected translation to substantial cardiovascular disease risk reduction. We believe MAR001 has the potential to become an important new therapeutic option for patients." Presentation Highlights:
